Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese
APCCC 2019: Synthesis — Optimal Treatment of Men with Newly Diagnosed Prostate Cancer – Philippine Endourological Society
Table 2 from Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15
Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
September 15, 2014 - What Constitutes High-Volume/Extensive Disease? - The ASCO Post
Presentazione standard di PowerPoint
ESOU 2019: Symptomatic Metastatic Castration-sensitive Hormone-naïve Prostate Cancer: Evidence from CHAARTED, LATITUDE, and STAMPEDE
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
New in management of hormone sensitive prostate cancer
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
Prostate cancer - The Lancet
Presentazione standard di PowerPoint
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial - The Lancet
ESMO 2019: Docetaxel for Hormone-Naïve Prostate Cancer: Results from Long-Term Follow-Up of Metastatic (M1) Patients in the STAMPEDE Randomized Trial and Sub Group Analysis by Metastatic Burden - Medical Oncologist Perspective
Piet Ost on Twitter: "What might PSMA PET-CT do in high risk PCa with its improved accuracy? It results in stage migration, mostly in the direction of finding more disease. How do
Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients - Shiota - 2021 - Cancer Science - Wiley Online Library
Radiotherapy (RT) to the primary tumour for men with newly- diagnosed metastatic hormone-naïve prostate cancer
Efficacy profiles of this study and CHAARTED trial | Download Scientific Diagram
Poly-Metastatic Hormone-Sensitive Disease - YouTube
Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
SYSTEMIC THERAPY OF PROSTATE CANCER - ppt download
ASCO GU 2020: Luminal B Subtype as a Predictive Biomarker of Docetaxel Benefit for Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer: A Correlative Study of E3805 CHAARTED
